Aducanumab Accepted for FDA Review with Priority Tag; Target Date Set for March 7

The US FDA has accepted a biologics license application (BLA) with priority review for Biogen’s and partner Eisai’s controversial Alzheimer’s drug aducanumab, aiming to make a decision by March next year. The two companies said on August 7 that the...read more